CYP46A1 and Cognitive impairment: Efforts to evaluate plasma 24-HC as an indicator of CYP46A1 activity have yielded inconsistent results, with some studies reporting elevated 24-HC in patients with mild cognitive impairment or early AD, and others reporting no significant differences compared to healthy controls [54,55,57,281].